This biotechnology company is focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiorenal diseases.
Betagenon
Developing treatments for chronic energy balance disorders.
